Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Pricing of pharmaceuticals is becoming a major challenge for health systems.

× No keyword cloud information.

12 in total

1. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.

Authors: Rick A Vreman; Thomas F Broekhoff; Hubert Gm Leufkens; Aukje K Mantel-Teeuwisse; Wim G Goettsch
Journal: Int J Environ Res Public Health Date: 2020-11-10 Impact factor: 3.390

2. Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction.

Authors: Sungju Kim; Jong Hyuk Lee
Journal: Healthcare (Basel) Date: 2020-07-26

3. EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?

Authors: L Schmidt; O Sehic; C Wild
Journal: J Pharm Policy Pract Date: 2021-04-28

4. Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care.

Authors: Ileana Mardare; Stephen M Campbell; Johanna C Meyer; Israel Abebrese Sefah; Amos Massele; Brian Godman
Journal: Front Pharmacol Date: 2022-01-14 Impact factor: 5.810

5. Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan.

Authors: Hideki Maeda; Ayano Okabe; Kenichi Sakakura; Daniel Bin Ng; Manabu Akazawa
Journal: BMC Health Serv Res Date: 2021-12-11 Impact factor: 2.655

Pricing of pharmaceuticals is becoming a major challenge for health systems.

1. Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis.

2. Price-Cutting Trends in New Drugs after Listing in South Korea: The Effect of the Reimbursement Review Pathway on Price Reduction.

3. EU FP7 research funding for an orphan drug (Orfadin®) and vaccine (Hep C) development: a success and a failure?

4. Enhancing Choices Regarding the Administration of Insulin Among Patients With Diabetes Requiring Insulin Across Countries and Implications for Future Care.

5. Relationships between developmental strategies for additional indications and price revisions for anticancer drugs in Japan.

Review 6. Mapping conflict of interests: scoping review.

7. Current and Future Treatment of Retinitis Pigmentosa.

8. Financing of Rare Diseases and Orphan Drugs in A Sanctioned Country: A Qualitative Study.

9. We Cannot Win the Access to Medicines Struggle Using the Same Thinking That Causes the Chronic Access Crisis.

10. Evaluating different adoption scenarios for TIL-therapy and the influence on its (early) cost-effectiveness.